Compare Bristol-Myers Squibb Co (BMY) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wynn Resorts, Limited — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Wynn Resorts, Limited trades at $97 (market cap $9.95B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.7× Wynn Resorts, Limited's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | WYNN | |
|---|---|---|
Market Cap | $116.30B | $9.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $133.34 |
52-Week Low | $42.60 | $94.78 |
Enterprise Value | $152.24B | $20.32B |
Dividend Yield | 4.42% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Wynn Resorts (WYNN) trades at $97.13, down 2.65% today, amid bearish technical signals and recent earnings misses. The stock faces margin pressure despite revenue growth, with net income margin declining to 5.14% in 2025. Analyst consensus remains bullish with a $134.30 price target, though technical indicators show resistance near $99-$103. Recent news highlights Q2 2026 earnings anticipation and luxury segment strength.
Outlook: Long-term potential exists via luxury focus and Macau recovery, but near-term risks include debt load ($10.5B), competitive pressures, and volatile earnings. Investors should weigh high analyst optimism against technical weakness and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
